FDA approves Alzheimer's drug lecanemab amid safety concerns

Nature. 2023 Jan;613(7943):227-228. doi: 10.1038/d41586-023-00030-3.
No abstract available

Keywords: Alzheimer's disease; Government; Neuroscience.

Publication types

  • News
  • Comment

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Antibodies, Monoclonal, Humanized* / adverse effects
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Drug Approval*
  • Humans
  • Patient Safety*
  • United States
  • United States Food and Drug Administration* / legislation & jurisprudence

Substances

  • lecanemab
  • Antibodies, Monoclonal, Humanized